Developer docs
API playgroundTry for free, no card

Search company profiles

Lys Therapeutics

Full company profile

uuid0002i5k

Namestring
Lys Therapeutics
Legal namestring
Lys Therapeutics – SAS
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Lys Therapeutics is a French privately-held biotechnology company founded in 2021 that develops first-in-class monoclonal antibody biotherapies for neurological diseases. The company's lead product candidate, LYS241 (also known as Glunozumab), is a fully humanized, Fc-silent IgG1 monoclonal antibody that targets the interaction between tissue plasminogen activator (tPA) and NMDA receptors in blood vessels. This mechanism restores blood-brain barrier integrity and counteracts neuroinflammation and neurodegenerative processes, addressing the pathophysiology of multiple neurological diseases through a single molecular entity. The company is developing two formulations: an intravenous formulation for acute indications such as ischemic stroke, and a subcutaneous formulation for chronic indications such as Parkinson's disease and multiple sclerosis.

The underlying technology emerged from foundational research at Inserm and the University of Caen-Normandy through the Blood and Brain @ Caen-Normandy Institute (BB@C), where the glunomab antibody was originally invented. Lys Therapeutics holds exclusive worldwide patent rights to this technology. Preclinical proof-of-concept has been established across multiple indications in peer-reviewed journals, including Journal of Neuroinflammation, Cell Reports, Blood Advances, Translational Stroke Research, Cell Death & Disease, JNeurosci, and Brain. The company is headquartered in Lyon with research laboratories in Caen and is preparing for first-in-human clinical trials.

The company is pre-revenue and operates a biopharmaceutical development and licensing business model. Future revenue is expected to come from licensing deals, co-development agreements, and eventual product commercialization upon regulatory approval. The company engages with potential pharmaceutical partners through major industry events (BIO International, BIO-Europe, JP Morgan Week). Total funding raised exceeds €25 million since founding, sourced from a €5.5 million seed round (HTH VC/Zambon equity plus Bpifrance grants), The Michael J. Fox Foundation grants (over $5.6 million total), France 2030 i-Nov funding, and other non-dilutive French government and Bpifrance programs. The company serves patients with neurovascular and neurodegenerative diseases, with stroke centers and pharmaceutical partners as secondary commercial stakeholders.

Short descriptiontext

Lys Therapeutics is a French preclinical biotechnology company developing LYS241, a first-in-class monoclonal antibody targeting the tPA-NMDAr interaction to treat neurovascular and neurodegenerative diseases including stroke, Parkinson's disease, and multiple sclerosis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapy, neurological disease treatment, blood-brain barrier, neurovascular therapeutics, neurodegenerative drug development
Industry4 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurological Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Biopharmaceutical Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue biotechnology company developing first-in-class monoclonal antibody LYS241. Expected revenue streams include licensing deals with pharmaceutical partners, co-development agreements, and eventual product commercialization upon regulatory approval.

lystherapeutics.com
2Strategic Partnerships and Collaborations
TypeLicensing Royalties
Description

The company is in discussions with international pharmaceutical companies for partnerships to advance clinical development and commercialization of LYS241 across multiple neurological indications.

lystherapeutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lys Therapeutics develops LYS241 (Glunozumab/Glunomab), a first-in-class fully humanized Fc-silent IgG1 monoclonal antibody that prevents pathological binding of tissue plasminogen activator (tPA) to NMDA receptors in blood vessels, restoring blood-brain barrier integrity to treat neurovascular and neurodegenerative diseases including ischemic stroke, Parkinson's disease and multiple sclerosis. The company is pre-commercial and advances its lead candidate through preclinical and early clinical development, intending to monetize via licensing and co-development partnerships with pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Significant reduction in ischemic brain damage and improved tissue recanalization when combined with thrombolytics (alteplase/tenecteplase) in preclinical stroke models
+3 more records
Product overview1 text field

Lys Therapeutics is a French biotechnology company developing first-in-class biotherapies for neurological diseases centered on its lead product candidate LYS241 (also referred to as Glunozumab or Glunomab). LYS241 is a fully humanized, Fc-silent IgG1 monoclonal antibody that targets the tPA-NMDAr axis to restore blood-brain barrier integrity. The company is advancing LYS241 through two distinct formulations: an intravenous formulation for acute/single-use applications (primarily ischemic stroke) and a subcutaneous formulation for chronic/repeated administration (for Parkinson's disease, multiple sclerosis, and other neurodegenerative conditions). The development program is designed as a pipeline-in-a-drug approach, with a single molecular entity addressing multiple neurological indications.

Product and service1 record
1LYS241 (Glunozumab / Glunomab)
CategoryNeurological biopharmaceutical / Monoclonal antibody therapy
Description

A first-in-class, fully humanized, Fc-silent IgG1 monoclonal antibody (drug substance) that counteracts neuroinflammatory and neurodegenerative processes by specifically preventing the binding of tissue plasminogen activator (tPA) on NMDA receptors within blood vessels, thereby restoring blood-brain barrier integrity without blocking physiological NMDAr function. Developed for treatment of neurovascular and neurodegenerative diseases including ischemic stroke, Parkinson's disease, multiple sclerosis and synucleinopathies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multi-year collaboration for Parkinson's disease research. Prof. Lawrence's team demonstrated involvement of tPA in Parkinson's pathophysiology and the role of tPA-NMDAr interaction in regulating inflammatory cell passage in the brain. Presented results at AD/PD conferences and published in peer-reviewed journals.

2Blood and Brain @ Caen-Normandy Institute (BB@C)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Foundational research partner. Prof. Denis Vivien (PU-PH) serves as Head of Science and President of Scientific Advisory Board. Institute provides research facilities at Cyceron campus in Caen. Co-inventor of glunomab antibody along with Prof. Richard Macrez.

lystherapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration through UMR-S 1237 PhIND (Physiopathology and Imaging of Neurological Disorders). Company holds exclusive worldwide patent rights to technology developed at Inserm and University of Caen-Normandy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner providing research collaboration and intellectual property through the joint research unit with Inserm.

5CYCERON
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research imaging and neuroscience center in Caen providing facilities and collaboration for preclinical research.

lystherapeutics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

European health innovation network providing support and recognition (Gold Track status) to accelerate healthcare innovation.

7Lyonbiopôle Auvergne-Rhône-Alpes
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Competitiveness cluster supporting healthcare innovation in the Lyon region, France.

lystherapeutics.com
8CHU de Caen Normandie
Strategic tierMinorTypeStrategic or Co-development Partner
Description

University hospital providing clinical research collaboration and expertise.

lystherapeutics.com
Strategic tierMinorTypeOthers
Description

Regional development agency supporting innovation and economic development in Normandy, France.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Technology transfer office supporting innovation from academic research to market application in Lyon region.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic research collaboration in neurodegeneration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major pharmaceutical company with neurological disease franchises including MS therapies (Gilenya, Kesimpta) and stroke/cardiovascular products; potential partner/acquirer for LYS241 in stroke and MS indications.

TypeDirect peer
Description

Clinical-stage biotech developing monoclonal antibodies for neurodegenerative diseases including Parkinson's disease (prasinezumab) and MS-related indications, with the same core thesis of targeting misfolded proteins via antibody therapeutics.

TypeDirect peer
Description

Clinical-stage biotech developing antibody-based therapeutics for neurodegeneration and lysosomal storage diseases, with programs for Parkinson's disease and MS — directly comparable mAb-platform competitor in CNS indications.

TypeDirect peer
Description

Swedish biotech developing monoclonal antibodies for neurodegenerative diseases, notably lecanemab (partnered with Eisai/Biogen) for Alzheimer's and a Parkinson's antibody program — directly comparable antibody-based neuro approach.

5AB Science
TypeDirect peer
Description

French clinical-stage biotech developing masitinib for neurodegenerative diseases (ALS, MS, Alzheimer's) and other inflammatory conditions; similar stage, geographic footprint, and neuro disease focus.

TypeDirect peer
Description

Belgian preclinical/early-clinical biotech developing disease-modifying therapies for Alzheimer's, Parkinson's, and diabetes; comparable preclinical neuro pipeline and small-cap European profile.

TypeEmerging player
Description

Swiss clinical-stage biotech developing vaccines and antibodies against neurodegenerative diseases (Alzheimer's, Parkinson's, MS) — overlapping neuro indication space with a slightly more advanced pipeline.

TypeBroad incumbent
Description

Major neurology-focused biopharmaceutical company with leading MS franchise (Tysabri, Tecfidera) and Parkinson's programs; Lys's Board Chairman Michel Vounatsos is Biogen's former CEO, making it a natural strategic acquirer/licensor.

TypeBroad incumbent
Description

Major biopharmaceutical company with Ocrelizumab (Ocrevus) for MS and a large neurological disease pipeline including mAb-based therapies — broad incumbent with overlapping CNS mAb capabilities.

TypeEmerging player
Description

Clinical-stage biotech with CNS-penetrating siRNA therapeutics including for neurodegeneration (e.g., ATTR amyloidosis programs); shares the platform-based biotech approach to CNS diseases and partnership-driven commercialization model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lys Therapeutics

Neurological Biopharmaceuticalslystherapeutics.com

Lys Therapeutics is a French preclinical biotechnology company developing LYS241, a first-in-class monoclonal antibody targeting the tPA-NMDAr interaction to treat neurovascular and neurodegenerative diseases including stroke, Parkinson's disease, and multiple sclerosis.

What Lys Therapeutics does

Lys Therapeutics is a French privately-held biotechnology company founded in 2021 that develops first-in-class monoclonal antibody biotherapies for neurological diseases. The company's lead product candidate, LYS241 (also known as Glunozumab), is a fully humanized, Fc-silent IgG1 monoclonal antibody that targets the interaction between tissue plasminogen activator (tPA) and NMDA receptors in blood vessels. This mechanism restores blood-brain barrier integrity and counteracts neuroinflammation and neurodegenerative processes, addressing the pathophysiology of multiple neurological diseases through a single molecular entity. The company is developing two formulations: an intravenous formulation for acute indications such as ischemic stroke, and a subcutaneous formulation for chronic indications such as Parkinson's disease and multiple sclerosis.

The underlying technology emerged from foundational research at Inserm and the University of Caen-Normandy through the Blood and Brain @ Caen-Normandy Institute (BB@C), where the glunomab antibody was originally invented. Lys Therapeutics holds exclusive worldwide patent rights to this technology. Preclinical proof-of-concept has been established across multiple indications in peer-reviewed journals, including Journal of Neuroinflammation, Cell Reports, Blood Advances, Translational Stroke Research, Cell Death & Disease, JNeurosci, and Brain. The company is headquartered in Lyon with research laboratories in Caen and is preparing for first-in-human clinical trials.

The company is pre-revenue and operates a biopharmaceutical development and licensing business model. Future revenue is expected to come from licensing deals, co-development agreements, and eventual product commercialization upon regulatory approval. The company engages with potential pharmaceutical partners through major industry events (BIO International, BIO-Europe, JP Morgan Week). Total funding raised exceeds €25 million since founding, sourced from a €5.5 million seed round (HTH VC/Zambon equity plus Bpifrance grants), The Michael J. Fox Foundation grants (over $5.6 million total), France 2030 i-Nov funding, and other non-dilutive French government and Bpifrance programs. The company serves patients with neurovascular and neurodegenerative diseases, with stroke centers and pharmaceutical partners as secondary commercial stakeholders.

Lys Therapeutics firmographics

Firmographics
Name
Lys Therapeutics
Legal name
Lys Therapeutics – SAS
Website
https://lystherapeutics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Lys Therapeutics is a French preclinical biotechnology company developing LYS241, a first-in-class monoclonal antibody targeting the tPA-NMDAr interaction to treat neurovascular and neurodegenerative diseases including stroke, Parkinson's disease, and multiple sclerosis.
Ownership category
akta.pro rank

Lys Therapeutics industry classification

Industry
Product category
Neurological Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Monoclonal antibody therapy
  • Neurological disease treatment
  • Blood-brain barrier
  • Neurovascular therapeutics
  • Neurodegenerative drug development

Where Lys Therapeutics is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Lys Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Development and Licensing: Pre-revenue biotechnology company developing first-in-class monoclonal antibody LYS241. Expected revenue streams include licensing deals with pharmaceutical partners, co-development agreements, and eventual product commercialization upon regulatory approval.
  2. Strategic Partnerships and Collaborations: The company is in discussions with international pharmaceutical companies for partnerships to advance clinical development and commercialization of LYS241 across multiple neurological indications.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Lys Therapeutics product offering

Product offering

Core offering

Lys Therapeutics develops LYS241 (Glunozumab/Glunomab), a first-in-class fully humanized Fc-silent IgG1 monoclonal antibody that prevents pathological binding of tissue plasminogen activator (tPA) to NMDA receptors in blood vessels, restoring blood-brain barrier integrity to treat neurovascular and neurodegenerative diseases including ischemic stroke, Parkinson's disease and multiple sclerosis. The company is pre-commercial and advances its lead candidate through preclinical and early clinical development, intending to monetize via licensing and co-development partnerships with pharmaceutical companies.

Product overview

Lys Therapeutics is a French biotechnology company developing first-in-class biotherapies for neurological diseases centered on its lead product candidate LYS241 (also referred to as Glunozumab or Glunomab). LYS241 is a fully humanized, Fc-silent IgG1 monoclonal antibody that targets the tPA-NMDAr axis to restore blood-brain barrier integrity. The company is advancing LYS241 through two distinct formulations: an intravenous formulation for acute/single-use applications (primarily ischemic stroke) and a subcutaneous formulation for chronic/repeated administration (for Parkinson's disease, multiple sclerosis, and other neurodegenerative conditions). The development program is designed as a pipeline-in-a-drug approach, with a single molecular entity addressing multiple neurological indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • LYS241 (Glunozumab / Glunomab) A first-in-class, fully humanized, Fc-silent IgG1 monoclonal antibody (drug substance) that counteracts neuroinflammatory and neurodegenerative processes by specifically preventing the binding of tissue plasminogen activator (tPA) on NMDA receptors within blood vessels, thereby restoring blood-brain barrier integrity without blocking physiological NMDAr function. Developed for treatment of neurovascular and neurodegenerative diseases including ischemic stroke, Parkinson's disease, multiple sclerosis and synucleinopathies.

Quantifiable outcome

  • Significant reduction in ischemic brain damage and improved tissue recanalization when combined with thrombolytics (alteplase/tenecteplase) in preclinical stroke models
  • +3 more outcomes

Companies that use Lys Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Lys Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Lys Therapeutics partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • University of Michigan (Prof. Daniel Lawrence)coreStrategic or Co-development PartnerMulti-year collaboration for Parkinson's disease research. Prof. Lawrence's team demonstrated involvement of tPA in Parkinson's pathophysiology and the role of tPA-NMDAr interaction in regulating inflammatory cell passage in the brain. Presented results at AD/PD conferences and published in peer-reviewed journals.
  • Blood and Brain @ Caen-Normandy Institute (BB@C)coreStrategic or Co-development PartnerFoundational research partner. Prof. Denis Vivien (PU-PH) serves as Head of Science and President of Scientific Advisory Board. Institute provides research facilities at Cyceron campus in Caen. Co-inventor of glunomab antibody along with Prof. Richard Macrez.
  • Inserm (Institut national de la santé et de la recherche médicale)coreStrategic or Co-development PartnerResearch collaboration through UMR-S 1237 PhIND (Physiopathology and Imaging of Neurological Disorders). Company holds exclusive worldwide patent rights to technology developed at Inserm and University of Caen-Normandy.
  • Université de Caen NormandiecoreStrategic or Co-development PartnerAcademic partner providing research collaboration and intellectual property through the joint research unit with Inserm.
  • CYCERONminorStrategic or Co-development PartnerResearch imaging and neuroscience center in Caen providing facilities and collaboration for preclinical research.
  • EIT HealthminorStrategic or Co-development PartnerEuropean health innovation network providing support and recognition (Gold Track status) to accelerate healthcare innovation.
  • Lyonbiopôle Auvergne-Rhône-AlpesminorStrategic or Co-development PartnerCompetitiveness cluster supporting healthcare innovation in the Lyon region, France.
  • CHU de Caen NormandieminorStrategic or Co-development PartnerUniversity hospital providing clinical research collaboration and expertise.
  • ADNormandie (Agence de Développement pour la Normandie)minorOthersRegional development agency supporting innovation and economic development in Normandy, France.
  • PulsalysminorStrategic or Co-development PartnerTechnology transfer office supporting innovation from academic research to market application in Lyon region.
  • UK Dementia Research InstituteminorStrategic or Co-development PartnerAcademic research collaboration in neurodegeneration.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Lys Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Novartis AG: Major pharmaceutical company with neurological disease franchises including MS therapies (Gilenya, Kesimpta) and stroke/cardiovascular products; potential partner/acquirer for LYS241 in stroke and MS indications.
  • Biogen Inc. Major neurology-focused biopharmaceutical company with leading MS franchise (Tysabri, Tecfidera) and Parkinson's programs; Lys's Board Chairman Michel Vounatsos is Biogen's former CEO, making it a natural strategic acquirer/licensor.
  • Roche / Genentech: Major biopharmaceutical company with Ocrelizumab (Ocrevus) for MS and a large neurological disease pipeline including mAb-based therapies — broad incumbent with overlapping CNS mAb capabilities.

Direct peers

  • Prothena Corporation: Clinical-stage biotech developing monoclonal antibodies for neurodegenerative diseases including Parkinson's disease (prasinezumab) and MS-related indications, with the same core thesis of targeting misfolded proteins via antibody therapeutics.
  • Denali Therapeutics: Clinical-stage biotech developing antibody-based therapeutics for neurodegeneration and lysosomal storage diseases, with programs for Parkinson's disease and MS — directly comparable mAb-platform competitor in CNS indications.
  • BioArctic AB: Swedish biotech developing monoclonal antibodies for neurodegenerative diseases, notably lecanemab (partnered with Eisai/Biogen) for Alzheimer's and a Parkinson's antibody program — directly comparable antibody-based neuro approach.
  • AB Science: French clinical-stage biotech developing masitinib for neurodegenerative diseases (ALS, MS, Alzheimer's) and other inflammatory conditions; similar stage, geographic footprint, and neuro disease focus.
  • reMYND NV: Belgian preclinical/early-clinical biotech developing disease-modifying therapies for Alzheimer's, Parkinson's, and diabetes; comparable preclinical neuro pipeline and small-cap European profile.

Emerging players

  • AC Immune SA: Swiss clinical-stage biotech developing vaccines and antibodies against neurodegenerative diseases (Alzheimer's, Parkinson's, MS) — overlapping neuro indication space with a slightly more advanced pipeline.
  • Alnylam Pharmaceuticals: Clinical-stage biotech with CNS-penetrating siRNA therapeutics including for neurodegeneration (e.g., ATTR amyloidosis programs); shares the platform-based biotech approach to CNS diseases and partnership-driven commercialization model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Lys Therapeutics social profiles

Digital presence

Lys Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lys Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Lys Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lys Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lys Therapeutics

What does Lys Therapeutics do?

Lys Therapeutics develops LYS241 (Glunozumab/Glunomab), a first-in-class fully humanized Fc-silent IgG1 monoclonal antibody that prevents pathological binding of tissue plasminogen activator (tPA) to NMDA receptors in blood vessels, restoring blood-brain barrier integrity to treat neurovascular and neurodegenerative diseases including ischemic stroke, Parkinson's disease and multiple sclerosis. The company is pre-commercial and advances its lead candidate through preclinical and early clinical development, intending to monetize via licensing and co-development partnerships with pharmaceutical companies.

Is Lys Therapeutics a public or private company?

Lys Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lys Therapeutics founded?

Lys Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Lys Therapeutics based?

Lys Therapeutics is headquartered in Lyon, France, in the Europe region.

How does Lys Therapeutics make money?

Two revenue lines are on record. Biopharmaceutical Development and Licensing is the primary driver. The others are strategic Partnerships and Collaborations.

Who are Lys Therapeutics's main competitors?

Broad incumbents on record are Novartis AG, Biogen Inc. and Roche / Genentech. Direct peers are Prothena Corporation, Denali Therapeutics, BioArctic AB, AB Science and reMYND NV. Emerging players are AC Immune SA and Alnylam Pharmaceuticals.

Does Lys Therapeutics have an API?

No public API is recorded for Lys Therapeutics.

What industry is Lys Therapeutics in?

Lys Therapeutics's product category is Neurological Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAGAFAN, Nonclinical Study Management & Regulatory Writing (IND-enabling). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyLys Therapeutics secures $29m for brain therapyFrench biotech Lys Therapeutics has raised over $29 million (€25 million) since its 2021 founding to advance its lead neurological therapy candidate LYS241 into first-in-human clinical trials, including a $5 million grant from The Michael J Fox Foundation for Parkinson's Research. The funding will support regulatory studies, manufacturing, and Phase 1a/1b clinical development for the antibody therapy designed to protect the blood-brain barrier. The company is pursuing a 'pipeline-in-a-drug' strategy, testing whether LYS241 could address multiple neurological conditions including Parkinson's disease, multiple system atrophy, and ischemic stroke.Pulse 2.0Lys Therapeutics Raises €25+ Million To Advance LYS241 Toward Clinical DevelopmentLys Therapeutics has raised more than €25 million since its founding in 2021, including a grant of more than $5 million from The Michael J. Fox Foundation for Parkinson's Research, to advance its lead candidate LYS241 toward clinical development. The company, a French biotechnology firm, is developing therapies targeting the tPA-NMDAr axis for neurodegenerative and neurovascular diseases including Parkinson's disease, synucleinopathies, and ischemic stroke. The funding will support regulatory studies, manufacturing readiness, and a biomarker-rich Phase 1a/1b clinical program targeting blood-brain barrier dysfunction, neuroinflammation, and excitotoxicity.Longevity.TechnologyLys Therapeutics raises over $27m to advance new treatments for Parkinson’s and strokeLys Therapeutics, a French biotech company headquartered in Lyon and Caen, has raised more than €25 million (approximately $27 million) since its 2021 founding, with over $5 million coming as a grant from The Michael J. Fox Foundation for Parkinson's Research alongside funding from Bpifrance, France 2030, and private investors. The proceeds will support regulatory studies, manufacturing readiness, and clinical entry of LYS241, a fully humanized Fc-silent monoclonal antibody designed to block pathological tPA-NMDA receptor interactions in neurological conditions. The Phase 1a/1b program is expected to assess safety, pharmacokinetics, and early proof-of-biology in cohorts of healthy volunteers and patients with Parkinson's disease, synucleinopathies, and ischemic stroke.FinSMEsLys Therapeutics Raises Over €25M in FundingLys Therapeutics raised over €25M in combined funding since its inception, including a $5M grant from The Michael J. Fox Foundation. The company will use the funds to complete regulatory studies, ensure manufacturing readiness, and finance the clinical entry of its lead asset through a Phase 1a/1b testing program.AInvestLys Therapeutics raises more than EUR 25 million to advance LYS241 toward clinical development in neurologyLys Therapeutics, a French biotechnology company, has secured over EUR 25 million in funding, including a $5 million grant from The Michael J. Fox Foundation for Parkinson's Research, to advance its lead candidate LYS241 toward first-in-human clinical trials for neurodegenerative diseases. LYS241 is a monoclonal antibody designed to restore blood-brain barrier integrity by neutralizing the pathological interaction between tissue plasminogen activator and NMDA receptors in the vascular compartment. The company is now preparing for clinical development following positive regulatory feedback and is fully financed through early-stage trials.PR NewswireLys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in NeurologyLys Therapeutics, a French biotechnology company specializing in neurovascular therapies, announced it has raised more than €25 million since its founding in 2021, including a grant of more than $5 million from The Michael J. Fox Foundation for Parkinson's Research, along with support from Bpifrance, France 2030, and private investors. The funding will advance the company's lead candidate LYS241, a first-in-class neurovascular monoclonal antibody targeting the tPA-NMDAr axis, through regulatory studies, manufacturing readiness, and a biomarker-rich Phase 1a/1b clinical program for Parkinson's disease, synucleinopathies including multiple system atrophy, and ischemic stroke.Normandie-IncubationNormandie IncubationLys Therapeutics, a biotechnology startup focused on neurological diseases, received a €570,000 grant from the Michael J. Fox Foundation. This funding supports the company's development of innovative treatments for patients with high medical needs in this sector.LystherapeuticsLys Therapeutics secures funding from The Michael J. Fox Foundation to accelerate the development of its drug candidate in Parkinson’s diseaseLys Therapeutics has secured more than $600,000 in funding from The Michael J. Fox Foundation to accelerate the preclinical development of its monoclonal antibody for Parkinson’s disease. This financial support facilitates the completion of research required to advance the drug candidate toward clinical trials. The initiative also aims to expand Lys Therapeutics' operational presence in the United States alongside its existing activities in Europe.LystherapeuticsLys Therapeutics announces a seed round of 5.5 million euros to prepare future clinical studies for its first-in-class monoclonal antibody targeting neurovascular and neurodegenerative disordersLys Therapeutics announced a 5.5 million euro seed round to fund preclinical studies and GMP production for its monoclonal antibody, glunomab/glunozumab, targeting neurovascular and neurodegenerative disorders. The financing includes 3 million euros in equity led by HTH VC and 2.5 million euros in support from Bpifrance and other banking institutions. These funds will enable the company to complete regulatory preclinical studies required for future clinical trials.Normandie-Univ3 lauréats dont 1 grand prix NormanDeepTech récompensés au concours d’innovation i-LabThree startups from the NormanDeepTech consortium were awarded on July 8, 2021, during the 2021 edition of the i-Lab innovation competition. The startups recognized are Lys Therapeutics, RMAN Sync, and Squair Tech, which stood out among 399 submissions, highlighting the support for innovative tech projects in the Normandy region. This achievement illustrates the effective collaboration and growth initiatives facilitated by the NormanDeepTech program.